M. Povey

发表

A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration

Kwang Nam Kim, N. Klein, Kyung-Hyo Kim, 2019, Human vaccines & immunotherapeutics.

A randomized trial assessing the efficacy, immunogenicity, and safety of vaccination with live attenuated varicella zoster virus-containing vaccines: ten-year follow-up in Russian children

Tatyana V. Ivleva, L. Namazova-Baranova, Y. Kovshirina, 2021, Human vaccines & immunotherapeutics.

Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12–15 Months

B. Innis, M. Mufson, C. Harrison, 2014, Journal of the Pediatric Infectious Diseases Society.

Randomised controlled trial showed long‐term efficacy, immunogenicity and safety of varicella vaccines in Norwegian and Swedish children

S. Silfverdal, C. Flodmark, A. Habib, 2021, Acta paediatrica.

Correlation of protection against varicella in a randomized Phase III varicella-containing vaccine efficacy trial in healthy infants.

V. Usonis, S. Esposito, R. Prymula, 2021, Vaccine.

Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial

A. Bavdekar, S. Datta, Shailesh Mehta, 2015, BMJ Open.

Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.

E. Di Paolo, M. Povey, S. Carryn, 2019, Vaccine.

Effectiveness of “Priorix” Against Measles and Mumps Diseases in Children Born After 2004 in the United Kingdom

E. Aris, G. Hall, B. Cheuvart, 2021, The Pediatric infectious disease journal.

No Consistent Evidence of Decreased Exposure to Varicella-Zoster Virus Among Older Adults in Countries with Universal Varicella Vaccination

R. Harpaz, R. G. van der Most, B. Cheuvart, 2021, The Journal of infectious diseases.

Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study

R. Abu-Elyazeed, M. Povey, Ouzama Henry, 2018, Human vaccines & immunotherapeutics.

Concomitant administration of a liquid formulation of human rotavirus vaccine (porcine circovirus-free) with routine childhood vaccines in infants in the United States: Results from a phase 3, randomized trial.

N. Klein, P. Silas, D. Bi, 2020, Vaccine.

Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study

S. Faust, M. Snape, K. Cathie, 2019, BMC Pediatrics.

Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study

T. Vesikari, L. Weiner, N. Klein, 2019, Journal of the Pediatric Infectious Diseases Society.

Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial.

V. Usonis, S. Esposito, S. Silfverdal, 2019, The Lancet. Infectious diseases.

The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: A phase IIIb, randomized, multi-center study in Italy.

P. Durando, S. Esposito, G. Gabutti, 2016, Vaccine.

The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children : A phase IIIb , randomized , multi-center study in Italy q

P. Durando, S. Esposito, M. Desole, 2016 .

Immunogenicity and safety of combined measles-mumps-rubella-varicella vaccine using new measles and rubella working seeds in healthy children in Taiwan and Singapore

Li-Min Huang, B. Lee, M. Povey, 2013, Human vaccines & immunotherapeutics.

Safety and reactogenicity of a liquid formulation of human rotavirus vaccine (porcine circovirus-free): A phase III, observer-blind, randomized, multi-country study.

Y. Lau, S. Halperin, Li-Min Huang, 2022, Vaccine.

Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)

C. Rojo, M. Sacristán, L. Sans, 2009, European Psychiatry.

Assessment of Mumps Virus-Specific Antibodies: Comparison of Plaque Reduction Neutralization Test and Enzyme-Linked Immunosorbent Assay Estimates

E. Di Paolo, D. Friel, P. Gillard, 2019, The Journal of infectious diseases.

Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries.

V. Usonis, H. Czajka, R. Prymula, 2021, Vaccine.

Varicella vaccine without human serum albumin versus licensed varicella vaccine in children during the second year of life: a randomized, double-blind, non-inferiority trial

R. Prymula, M. Povey, A. Kulcsár, 2016, BMC Pediatrics.

Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine: an open-labeled, randomized trial in healthy Korean children

O. Nicholson, S. Cha, Hwang-Min Kim, 2013, Clinical and experimental vaccine research.

Immunogenicity and safety of a two‐dose live attenuated varicella vaccine given to adults following autologous hematopoietic stem cell transplantation

J. Szer, H. Prince, J. Sasadeusz, 2014, Transplant infectious disease : an official journal of the Transplantation Society.

Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study

Andrea A. Berry, N. Chiu, T. Vesikari, 2018, Human vaccines & immunotherapeutics.

Comparison of a glycoprotein E-based ELISA with a varicella-zoster whole-virus ELISA for the quantification of varicella vaccine immune responses in young children.

E. Di Paolo, P. Gillard, M. Povey, 2020, Vaccine.

One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life.

R. Gasparini, G. Gabutti, M. Desole, 2018, Vaccine.

Two-year antibody persistence in children vaccinated at 12–15 months with a measles-mumps-rubella virus vaccine without human serum albumin

Andrea A. Berry, B. Innis, M. Mufson, 2017, Human vaccines & immunotherapeutics.

Clinical trials show similar safety outcomes including febrile convulsion rates for GSK’s and Merck’s measles-mumps-rubella (MMR) vaccines

G. Casabona, R. Abu-Elyazeed, M. Povey, 2023, Human vaccines & immunotherapeutics.

Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12–15 Months

B. Innis, M. Mufson, C. Harrison, 2014, Journal of the Pediatric Infectious Diseases Society.

Reduced polypharmacy in patients enrolled in the electronic schizophrenia adherence registry (E-STAR) and treated with risperidone long-acting injection (RLAI) for 6 months

M. Povey, H. Hustig, J. Olivares, 2007, European psychiatry.

Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine: an open-labeled, randomized trial in healthy Korean children

O. Nicholson, S. Cha, Hwang-Min Kim, 2013, Clinical and experimental vaccine research.

Clinically- versus serologically-identified varicella: A hidden infection burden. A ten-year follow-up from a randomized study in varicella-endemic countries

P. Gillard, M. Povey, Stéphane Carryn, 2021, Human vaccines & immunotherapeutics.